A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon‐derived peptide levels

Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived pe...

Full description

Saved in:
Bibliographic Details
Published inJournal of diabetes investigation Vol. 14; no. 5; pp. 648 - 658
Main Authors Kobayashi, Masaki, Maruyama, Nobuhiro, Yamamoto, Yukako, Togawa, Takeshi, Ida, Takanori, Yoshida, Morikatsu, Miyazato, Mikiya, Kitada, Masahisa, Hayashi, Yoshitaka, Kashiwagi, Atsunori, Kitamura, Tadahiro
Format Journal Article
LanguageEnglish
Published Japan John Wiley & Sons, Inc 01.05.2023
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. Materials and Methods A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system. Results The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA. Conclusions The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
AbstractList Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.AIMS/INTRODUCTIONGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.MATERIALS AND METHODSA new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.The new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.RESULTSThe new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.CONCLUSIONSThe new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
Abstract Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. Materials and Methods A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system. Results The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA. Conclusions The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. Materials and Methods A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system. Results The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA. Conclusions The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system. The new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA. The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
Aims/IntroductionGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.Materials and MethodsA new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.ResultsThe new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.ConclusionsThe new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
Author Yoshida, Morikatsu
Maruyama, Nobuhiro
Ida, Takanori
Kobayashi, Masaki
Hayashi, Yoshitaka
Yamamoto, Yukako
Kitada, Masahisa
Miyazato, Mikiya
Togawa, Takeshi
Kitamura, Tadahiro
Kashiwagi, Atsunori
AuthorAffiliation 3 Department of Diabetes and Endocrinology Omi Medical Center Shiga Japan
2 Immuno‐Biological Laboratories Co., Ltd Gunma Japan
5 Division for Identification and Analysis of Bioactive Peptides, Department of Bioactive Peptides, Frontier Science Research Center University of Miyazaki Miyazaki Japan
1 Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation Gunma University Gunma Japan
7 Kitada Internal Medicine Clinic Gifu Japan
6 Department of Biochemistry National Cerebral and Cardiovascular Center Research Institute Osaka Japan
8 Division of Stress Adaptation and Protection, Department of Endocrinology, Research Institute of Environmental Medicine Nagoya University Nagoya Japan
4 Department of Bariatric and Metabolic Surgery Omi Medical Center Shiga Japan
AuthorAffiliation_xml – name: 3 Department of Diabetes and Endocrinology Omi Medical Center Shiga Japan
– name: 2 Immuno‐Biological Laboratories Co., Ltd Gunma Japan
– name: 5 Division for Identification and Analysis of Bioactive Peptides, Department of Bioactive Peptides, Frontier Science Research Center University of Miyazaki Miyazaki Japan
– name: 8 Division of Stress Adaptation and Protection, Department of Endocrinology, Research Institute of Environmental Medicine Nagoya University Nagoya Japan
– name: 1 Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation Gunma University Gunma Japan
– name: 4 Department of Bariatric and Metabolic Surgery Omi Medical Center Shiga Japan
– name: 6 Department of Biochemistry National Cerebral and Cardiovascular Center Research Institute Osaka Japan
– name: 7 Kitada Internal Medicine Clinic Gifu Japan
Author_xml – sequence: 1
  givenname: Masaki
  surname: Kobayashi
  fullname: Kobayashi, Masaki
  organization: Gunma University
– sequence: 2
  givenname: Nobuhiro
  surname: Maruyama
  fullname: Maruyama, Nobuhiro
  organization: Immuno‐Biological Laboratories Co., Ltd
– sequence: 3
  givenname: Yukako
  surname: Yamamoto
  fullname: Yamamoto, Yukako
  organization: Omi Medical Center
– sequence: 4
  givenname: Takeshi
  surname: Togawa
  fullname: Togawa, Takeshi
  organization: Omi Medical Center
– sequence: 5
  givenname: Takanori
  surname: Ida
  fullname: Ida, Takanori
  organization: University of Miyazaki
– sequence: 6
  givenname: Morikatsu
  surname: Yoshida
  fullname: Yoshida, Morikatsu
  organization: National Cerebral and Cardiovascular Center Research Institute
– sequence: 7
  givenname: Mikiya
  surname: Miyazato
  fullname: Miyazato, Mikiya
  organization: National Cerebral and Cardiovascular Center Research Institute
– sequence: 8
  givenname: Masahisa
  surname: Kitada
  fullname: Kitada, Masahisa
  organization: Kitada Internal Medicine Clinic
– sequence: 9
  givenname: Yoshitaka
  orcidid: 0000-0002-7557-4303
  surname: Hayashi
  fullname: Hayashi, Yoshitaka
  organization: Nagoya University
– sequence: 10
  givenname: Atsunori
  orcidid: 0000-0002-6049-3236
  surname: Kashiwagi
  fullname: Kashiwagi, Atsunori
  organization: Omi Medical Center
– sequence: 11
  givenname: Tadahiro
  orcidid: 0000-0001-8809-8740
  surname: Kitamura
  fullname: Kitamura, Tadahiro
  email: kitamura@gunma-u.ac.jp
  organization: Gunma University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36729958$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAUhSNUREvpghdAltiUxbSx48T2Co1KgUEjsQDWlse5nvHIEwc7mdHseASeigfhSXDmp9ACXjiWfc7n65vzNDtpfANZ9hznVziN62Vtr3AhePUoOyM5zUcYE3pyt8bVaXYR4zJPo-C8qtiT7LSoGBGi5GfZjzFqYOO2qIY1ON9Cjeau12ruGxRVU2-sXqDb6eTTGNmI-gimd8j4gFY-AFJa90F18NsDa-V61dm07BZqmAAlTYCmS5ckf_0XNl3Uz5agu4g2tlsgcAnSJWHrVFwp1AZ_xP_89r2GYNfDIbSdrQG5oe74LHtslItwcfieZ1_e3n6-eT-afnw3uRlPR7osaDUydDYzjFNMtcqJBoGLkqd2FURrACE0z6mCXJdY0KoShtZYFJoJDtzgiuPiPJvsubVXS9kGu1JhK72ycrfhw1yq0FntQMKMCVCcGFYYKkyteMk4yauSYJMbRhPr9Z7V9rMV1Dq1KCh3D3r_pLELOfdriXOMhcA8ES4PhOC_9hA7ubJRg3OqAd9HSRhLD6GMDdKXD6RL34cm9UoSnoJBuMBlUr34s6S7Wo55SYLrvUAHH2MAI7Xtdr87VWhdKk0OoZQplHIXyuR49cBxhP5Le6BvrIPt_4Xyw5vJ3vELLPr07Q
CitedBy_id crossref_primary_10_1111_jdi_14249
crossref_primary_10_1038_s41574_025_01100_4
crossref_primary_10_1016_j_foodchem_2023_137947
crossref_primary_10_3390_nu15183913
crossref_primary_10_1007_s13340_024_00704_x
crossref_primary_10_2116_bunsekikagaku_72_233
crossref_primary_10_1210_clinem_dgae174
crossref_primary_10_1210_clinem_dgae460
Cites_doi 10.1016/S0140-6736(18)30726-8
10.1111/dom.12672
10.1016/S0140-6736(75)92375-2
10.2337/dc15-1643
10.1111/jdi.13325
10.1155/2016/8352957
10.1111/jdi.12797
10.2337/db16-0994
10.1038/nm1168
10.1007/s00125-014-3283-z
10.1210/endo-119-4-1467
10.1016/j.ebiom.2016.03.034
10.1111/jdi.12400
10.1210/js.2018-00142
10.1507/endocrj.EJ20-0079
10.2337/db16-0240
10.1210/er.2018-00117
10.1007/s00216-017-0534-0
10.1016/j.celrep.2019.01.047
10.1172/JCI112846
10.1007/s13340-010-0011-x
10.1016/j.soard.2018.01.039
10.1507/endocrj.EJ18-0372
10.1111/jdi.13110
10.1111/j.1463-1326.2011.01452.x
10.1007/s00595-015-1134-2
10.1126/science.1089999
10.1080/00365513.2021.2016943
10.1210/me.2009-0296
ContentType Journal Article
Copyright 2023 The Authors. published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
– notice: 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
– notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TM
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1111/jdi.13986
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Nucleic Acids Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journal Collection
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Newly developed glucagon sandwich ELISA
EISSN 2040-1124
EndPage 658
ExternalDocumentID oai_doaj_org_article_eb79ea82f73f49fda8578206521f0f74
PMC10119918
36729958
10_1111_jdi_13986
JDI13986
Genre article
Journal Article
GeographicLocations United States--US
Japan
GeographicLocations_xml – name: United States--US
– name: Japan
GroupedDBID ---
05W
0R~
1OC
24P
31~
4.4
50Y
5DZ
5VS
7X7
8-0
8-1
8FI
8FJ
AAHHS
AANHP
AAZKR
ABDBF
ABJNI
ABUWG
ACBWZ
ACCFJ
ACCMX
ACGFO
ACPRK
ACRPL
ACUHS
ACXQS
ACYXJ
ADBBV
ADKYN
ADNMO
ADPDF
ADRAZ
ADZMN
AEEZP
AEGXH
AENEX
AEQDE
AFKRA
AHMBA
AIAGR
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
ASPBG
AVUZU
AVWKF
AZFZN
BAWUL
BCNDV
BDRZF
BENPR
BPHCQ
BVXVI
CAG
CCPQU
COF
DIK
EBD
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
KQ8
LH4
LW6
M48
MY.
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
RX1
SUPJJ
TEORI
UKHRP
WIN
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TM
7XB
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c5346-f4bbf78414ca02ce9135812432ccee99c804ae0c5194669f4d193c798e8f16813
IEDL.DBID 7X7
ISSN 2040-1116
2040-1124
IngestDate Wed Aug 27 01:31:44 EDT 2025
Thu Aug 21 18:38:27 EDT 2025
Fri Jul 11 09:51:32 EDT 2025
Mon Jul 14 09:55:25 EDT 2025
Wed Feb 19 02:24:10 EST 2025
Tue Jul 01 02:48:50 EDT 2025
Thu Apr 24 23:04:16 EDT 2025
Wed Jan 22 16:24:02 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Glucagon
Sandwich ELISA
Glicentin
Language English
License Attribution-NonCommercial-NoDerivs
2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5346-f4bbf78414ca02ce9135812432ccee99c804ae0c5194669f4d193c798e8f16813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8809-8740
0000-0002-6049-3236
0000-0002-7557-4303
OpenAccessLink https://www.proquest.com/docview/2803828915?pq-origsite=%requestingapplication%
PMID 36729958
PQID 2803828915
PQPubID 1006415
PageCount 658
ParticipantIDs doaj_primary_oai_doaj_org_article_eb79ea82f73f49fda8578206521f0f74
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10119918
proquest_miscellaneous_2771944778
proquest_journals_2803828915
pubmed_primary_36729958
crossref_citationtrail_10_1111_jdi_13986
crossref_primary_10_1111_jdi_13986
wiley_primary_10_1111_jdi_13986_JDI13986
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2023
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Richmond
– name: Hoboken
PublicationTitle Journal of diabetes investigation
PublicationTitleAlternate J Diabetes Investig
PublicationYear 2023
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 1987; 79
2009; 23
1986; 119
2019; 3
2019; 10
2017; 66
2011; 13
2016; 2016
2016; 18
2016; 39
2018; 9
2018; 39
2016; 7
2018; 391
2017; 409
2021; 12
2010; 1
2022; 82
2019; 66
2019; 26
2016; 65
1975; 1
2014; 57
2020; 67
1975; 187
2005; 11
2016; 46
2018; 14
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_24_1
e_1_2_7_23_1
e_1_2_7_22_1
e_1_2_7_21_1
e_1_2_7_20_1
References_xml – volume: 57
  start-page: 1919
  year: 2014
  end-page: 1926
  article-title: Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
  publication-title: Diabetologia
– volume: 46
  start-page: 268
  year: 2016
  end-page: 274
  article-title: Potential mechanisms mediating improved glycemic control after bariatric/metabolic surgery
  publication-title: Surg Today
– volume: 1
  start-page: 14
  year: 1975
  end-page: 16
  article-title: The essential role of glucagon in the pathogenesis of diabetes mellitus
  publication-title: Lancet
– volume: 391
  start-page: 2607
  year: 2018
  end-page: 2618
  article-title: MEDI0382, a GLP‐1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double‐blind, ascending dose and phase 2a study
  publication-title: Lancet
– volume: 409
  start-page: 5911
  year: 2017
  end-page: 5918
  article-title: Accurate analytical method for human plasma glucagon levels using liquid chromatography‐high resolution mass spectrometry: comparison with commercially available immunoassays
  publication-title: Anal Bioanal Chem
– volume: 187
  start-page: 544
  year: 1975
  end-page: 547
  article-title: Glucagon: Role in the hyperglycemia of diabetes mellitus
  publication-title: Science
– volume: 82
  start-page: 75
  year: 2022
  end-page: 83
  article-title: On measurements of glucagon secretion in healthy, obese, and roux‐en‐Y gastric bypass operated individuals using sandwich ELISA
  publication-title: Scand J Clin Lab Invest
– volume: 18
  start-page: 795
  year: 2016
  end-page: 802
  article-title: Effects of multiple ascending doses of the glucagon receptor antagonist PF‐06291874 in patients with type 2 diabetes mellitus
  publication-title: Diabetes Obes Metab
– volume: 23
  start-page: 1990
  year: 2009
  end-page: 1999
  article-title: Mice deficient for glucagon gene‐derived peptides display normoglycemia and hyperplasia of islet {alpha}‐cells but not of intestinal L‐cells
  publication-title: Mol Endocrinol
– volume: 3
  start-page: 42
  year: 2019
  end-page: 51
  article-title: Postprandial plasma glucagon kinetics in type 2 diabetes mellitus: comparison of immunoassay and mass spectrometry
  publication-title: J Endocr Soc
– volume: 1
  start-page: 99
  year: 2010
  end-page: 103
  article-title: Laparoscopic sleeve gastrectomy leads to rapid improvement of glucose tolerance and insulin secretion with enhanced glucagon‐like peptide (GLP‐1) secretion
  publication-title: Diabetol Int
– volume: 14
  start-page: 562
  year: 2018
  end-page: 568
  article-title: Gastrectomy with roux‐en‐Y reconstruction as a lean model of bariatric surgery
  publication-title: Surg Obes Relat Dis
– volume: 13
  start-page: 89
  issue: Suppl 1
  year: 2011
  end-page: 94
  article-title: Regulation of glucagon secretion by incretins
  publication-title: Diabetes Obes Metab
– volume: 67
  start-page: 903
  year: 2020
  end-page: 922
  article-title: Plasma glucagon levels measured by sandwich ELISA are correlated with impaired glucose tolerance in type 2 diabetes
  publication-title: Endocr J
– volume: 12
  start-page: 286
  year: 2021
  end-page: 289
  article-title: Pseudo‐hyperglucagonemia was observed in pancreatectomized patients when measured by glucagon sandwich enzyme‐linked immunosorbent assay
  publication-title: J Diabetes Investig
– volume: 39
  start-page: 1241
  year: 2016
  end-page: 1249
  article-title: Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12‐ and 24‐week phase 2 studies
  publication-title: Diabetes Care
– volume: 65
  start-page: 3473
  year: 2016
  end-page: 3481
  article-title: Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation
  publication-title: Diabetes
– volume: 119
  start-page: 1467
  year: 1986
  end-page: 1475
  article-title: Glucagon‐like peptides GLP‐1 and GLP‐2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas*
  publication-title: Endocrinology
– volume: 11
  start-page: 90
  year: 2005
  end-page: 94
  article-title: Free fatty acids regulate gut incretin glucagon‐like peptide‐1 secretion through GPR120
  publication-title: Nat Med
– volume: 39
  start-page: 719
  year: 2018
  end-page: 738
  article-title: Targeting the incretin/glucagon system with triagonists to treat diabetes
  publication-title: Endocr Rev
– volume: 2016
  year: 2016
  article-title: Inability of some commercial assays to measure suppression of glucagon secretion
  publication-title: J Diabetes Res
– volume: 79
  start-page: 547
  year: 1987
  end-page: 556
  article-title: Hyperglucagonemia and insulin‐mediated glucose metabolism
  publication-title: J Clin Invest
– volume: 66
  start-page: 235
  year: 2017
  end-page: 240
  article-title: Glucagon and amino acids are linked in a mutual feedback cycle: the liver‐α‐cell axis
  publication-title: Diabetes
– volume: 10
  start-page: 1391
  year: 2019
  end-page: 1393
  article-title: Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations
  publication-title: J Diabetes Investig
– volume: 7
  start-page: 324
  year: 2016
  end-page: 331
  article-title: Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme‐linked immunosorbent assay
  publication-title: J Diabetes Investig
– volume: 9
  start-page: 464
  year: 2018
  end-page: 472
  article-title: Regulation of amino acid metabolism and alpha‐cell proliferation by glucagon
  publication-title: J Diabetes Investig
– volume: 66
  start-page: 663
  year: 2019
  end-page: 675
  article-title: Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes
  publication-title: Endocr J
– volume: 26
  start-page: 1399
  year: 2019
  end-page: 408.e6
  article-title: Important role of the GLP‐1 Axis for glucose homeostasis after bariatric surgery
  publication-title: Cell Rep
– volume: 7
  start-page: 112
  year: 2016
  end-page: 120
  article-title: Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass‐spectrometry based profiling of human plasma
  publication-title: EBioMedicine
– ident: e_1_2_7_11_1
  doi: 10.1016/S0140-6736(18)30726-8
– ident: e_1_2_7_6_1
  doi: 10.1111/dom.12672
– ident: e_1_2_7_3_1
  doi: 10.1016/S0140-6736(75)92375-2
– ident: e_1_2_7_5_1
  doi: 10.2337/dc15-1643
– ident: e_1_2_7_19_1
  doi: 10.1111/jdi.13325
– ident: e_1_2_7_27_1
  doi: 10.1155/2016/8352957
– ident: e_1_2_7_8_1
  doi: 10.1111/jdi.12797
– ident: e_1_2_7_7_1
  doi: 10.2337/db16-0994
– ident: e_1_2_7_30_1
  doi: 10.1038/nm1168
– ident: e_1_2_7_13_1
  doi: 10.1007/s00125-014-3283-z
– ident: e_1_2_7_28_1
  doi: 10.1210/endo-119-4-1467
– ident: e_1_2_7_29_1
  doi: 10.1016/j.ebiom.2016.03.034
– ident: e_1_2_7_16_1
  doi: 10.1111/jdi.12400
– ident: e_1_2_7_15_1
  doi: 10.1210/js.2018-00142
– ident: e_1_2_7_26_1
  doi: 10.1507/endocrj.EJ20-0079
– ident: e_1_2_7_24_1
  doi: 10.2337/db16-0240
– ident: e_1_2_7_10_1
  doi: 10.1210/er.2018-00117
– ident: e_1_2_7_14_1
  doi: 10.1007/s00216-017-0534-0
– ident: e_1_2_7_20_1
  doi: 10.1016/j.celrep.2019.01.047
– ident: e_1_2_7_4_1
  doi: 10.1172/JCI112846
– ident: e_1_2_7_23_1
  doi: 10.1007/s13340-010-0011-x
– ident: e_1_2_7_18_1
  doi: 10.1016/j.soard.2018.01.039
– ident: e_1_2_7_25_1
  doi: 10.1507/endocrj.EJ18-0372
– ident: e_1_2_7_9_1
  doi: 10.1111/jdi.13110
– ident: e_1_2_7_12_1
  doi: 10.1111/j.1463-1326.2011.01452.x
– ident: e_1_2_7_22_1
  doi: 10.1007/s00595-015-1134-2
– ident: e_1_2_7_2_1
  doi: 10.1126/science.1089999
– ident: e_1_2_7_17_1
  doi: 10.1080/00365513.2021.2016943
– ident: e_1_2_7_21_1
  doi: 10.1210/me.2009-0296
SSID ssj0000388667
Score 2.3499238
Snippet Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently...
Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by...
Aims/IntroductionGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently...
A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more...
Abstract Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 648
SubjectTerms Cloning
Diabetes
Diabetes Mellitus
Enzyme-linked immunosorbent assay
Enzyme-Linked Immunosorbent Assay - methods
Gastrectomy
Gastrointestinal surgery
Glicentin
Glucagon
Glucose
Glucose Intolerance - diagnosis
Glucose tolerance
Humans
Intolerance
Laparoscopy
Liquid chromatography
Monoclonal antibodies
Obesity
Original
Pathophysiology
Peptide Hormones
Peptides
Plasma
Polypeptides
Proglucagon
Sandwich ELISA
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journal Collection
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtUwELVQF4gNojwvFGQQi24CceL4sbxAq7aibKBSd5GfNNIltyJNETs-ga_iQ_gSZpw0vVctYsMmiuJHHHucOWOPzxDy0uoQcstsppVTGfdgsKpch0wb7l0VQQGnGEuHH8TeET84ro5XQn2hT9hADzx03OtgpQ5GFVGWkevojUICdlCcBYt5lIkJFHTeijGV_sGlUiKFjy3QZQ4mtBhphZIbj29eAfLB89Mryihx9l8HNK_6S67i2KSIdu-Q2yOCpPOh5ZvkRmjvkpuH4x75PfJrTgEqL77T8TxU8BT90s3nZUs70_pvjTuhO-_3P85p09G-C7FfUICuFF1uqXGuR_aIyzKXfOAUl9nhEqgbWJ3gJVDeX6kWXtRbXODpKK7zUjzDDnV6egpY_Yuh6BQ2Vv_7x08Pk-AcE9HBxge6wHZ398nR7s6nt3vZGK0hc1XJRRa5tRF3MbkzeeGCZkitVvCycKCItXYq5ybkDiAjF0JH7gE7OqlVUJEJxcoHZKNdtuERocwUnrlc8WjBgBGlEdJpKC6dd7aUcUa2L4atdiOVOUbUWNSTSeObOo3wjLyYsp4O_B3XZXqDYz9lQMrt9AAEsR4Fsf6XIM7I1oXk1ON_oKsx9hfatKyakedTMsxg3JYxbVj2kEdK6BIupZqRh4OgTS0pBRg_uoIUtSaCa01dT2mbk8QSzpDNTzMoup2k9e-fXx-82083j_9HPzwhtwoAgoNT6BbZOPvah6cA3M7sszRH_wA2EEN2
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZKkRAXxLuBggzi0MtW-_D6cUAoQKu2IlwgUm8rrx_tSmFTsl2g_48fxozjbIkauERR7PF61zOZb-zZbwh5Uyvn0jqrEyWNTJiFgFWmyiVKM2tKDw441FiafOZHU3ZyWp5ukVWNzfgAu42hHdaTmi5m-7--X70Dg387ZOXYZh-AjOS3yG1wSALtcxJRfvhDLqTkoZZsjvlzIMIjx9Ca9JpnCgT-m1DnzeTJv0Ft8EqH98m9CCfpeLn-D8iWax-SO5N4YP6I_B5TwM2zKxpfjnKWYpK6Ppu3tNOt_dmYc3rw6fjLmDYd7Tvn-xkFHEsx_5ZqY3qkkriWuSYHp7jnDh-OmiXFE1wE5O2NYeFCfY27PR3FTV-KL7TDmJZeAHD_pilmiMXhEwv28AObMNfGOjrDWXePyfTw4OuHoyQWbkhMWTCeeFbXHg80mdFpbpzKkGUtZ0VuwCcrZWTKtEsNoEfGufLMAow0QkknfcZlVjwh2-28dTuEZjq3mUkl8zXEMrzQXBgF4sJYUxfCj8jeatEqE1nNsbjGrBqiG9tUYX1H5PXQ9WJJ5bGp03tc-aEDsm-HH-aLsyoac-VqoZyWuReFZ8pbLbEoAIC5PPOpF2xEdld6U600usIyYBjeZuWIvBqawZjxhEa3bt5DHyHgkTAh5Ig8XarZMJOCQxykSmiRawq4NtX1lrY5D4ThGRL7qQxE94Ku_vv2q5OPx-HLs__fwnNyNwe0t8z83CXbl4vevQB0dlm_DLb3BwKJOw0
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkRAXxLuBggzi0EtQHo4f4rRAq7aiCAkq9Rb52UZaslXTgLjxE_hV_BB-CTNONu2qReKyitYex4k98Tfj8TeEvDLK-8zkJlXSypQ5MFhlpnyqNHO2CrAAxxxLBx_57iHbP6qO1sib5VmYgR9icrihZsTvNSq4Nt1lJXfNa4Avkt8gN_FoLRLnF-zT5GBBmhMeM8gWGDUHQnxkFoqRPEvplfUo0vZfhzWvhkxehrJxLdq5S-6MIJLOhlG_R9Z8e5_cOhi3yR-Q3zMKaHn-g45HoryjGJqujxct7XTrvjf2hG5_2Ps8o01H-86Hfk4BvVKMuqXa2h4JJC5kLijBKXra4cdTOxA7wU1A3l1pFm7UG_TxdBRdvRSPsUObjp4CXP-qKcaFjc3_-fnLgR58w0KMsXGezrHf3UNyuLP95d1uOiZsSG1VMp4GZkzAjUxmdVZYr3JkVytYWVhYi5WyMmPaZxZQI-NcBeYAPlqhpJch5zIvH5H1dtH6DUJzXbjcZpIFAzYMLzUXVoG4sM6aUoSEbC2HrbYjmzkm1ZjXk1XjmjqOcEJeTlVPBwqP6yq9xbGfKiDrdvxjcXZcj0pceyOU17IIogxMBaclJgMAEFfkIQuCJWRzOXPq8VPQ1Zj-C83avErIi6kYlBh3ZnTrFz3UEQJeCRNCJuTxMNGmnpQc7B9VQYlcmYIrXV0taZuTSBSeI6GfykF0K87Wfz9-vf9-L148-f-qT8ntAhDfEP25SdbPz3r_DBDauXkeNfEvnac7IQ
  priority: 102
  providerName: Wiley-Blackwell
Title A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon‐derived peptide levels
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdi.13986
https://www.ncbi.nlm.nih.gov/pubmed/36729958
https://www.proquest.com/docview/2803828915
https://www.proquest.com/docview/2771944778
https://pubmed.ncbi.nlm.nih.gov/PMC10119918
https://doaj.org/article/eb79ea82f73f49fda8578206521f0f74
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZoKyEuiDeBsjKIQy-BPLyxfUJb2Kqt2KoCKu0tcvxoIy3ZpWlA_D9-GDNeb7arFi5RFD_ixGP7m_H4G0LeVtLapEqrWAotYmZAYRWJtLFUzOihgwXYx1ianBSHZ-x4OpwGg1sb3CpXc6KfqM1co438PUZRQu0gHX5Y_IgxahTuroYQGltkB6nL0KWLT3lvY0Gmk8IHkc3QcQ6GdRHIhbwzj6nfAf7BU9TXliTP3H8b3LzpNXkdzfrl6OABuR9wJB0tO_4huWObR-TuJOyUPyZ_RhQA8-w3DaeirKHona7O5w1tVWN-1fqCjj8ffR3RuqVda103owBgKTreUqV1hxwS6zJrVnCKxna4WKqX3E7wEihvblQLL-oqNPO0FK29FE-yQ52GLgCxf1cUXcNC9bGBgfATk9DJxlg6w1a3T8jZwfjbx8M4RGyI9TBnRexYVTncyWRaJZm2MkV6tYzlmYbFWEotEqZsogE2sqKQjhnAj5pLYYVLC5HmT8l2M2_sc0JTlZlUJ4K5CpSYIlcF1xKKc210lXMXkb1Vp5U60JljVI1Z2as1pi59_0bkTZ91seTwuC3TPvZ8nwFpt_2D-eV5GUZxaSsurRKZ47lj0hklMBoAoLgsdYnjLCK7K7kpw1zQlmvJjcjrPhlGMW7NqMbOO8jDOfwSxrmIyLOlmPUtyQtQgEC4IyI2BHCjqZspTX3hmcJTZPSTKRTd87L6788vjz8d-ZsX__-El-ReBjBv6fK5S7avLjv7CmDZVTUgWxk7HfgROCA7--OT0y8Db-KA64SJv6EgPZY
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKgEXxJtAAYNA6mXLPpy1fUAopamSNokQtFJvi9ePNlLYhG6Xqn-KX8EPY2Z3s2nUwq2XKIof682Mx9_Y428IeZdKa_00SD0ptPCYAYdV-NJ6UjGjOw4W4DLH0mgc9w_Z3lHnaI38XtyFwbDKhU0sDbWZadwj_4BZlNA7CDqf5j89zBqFp6uLFBqVWuzbi3Nw2fKPgx2Q7_sw3O0dfO57dVYBT3ciFnuOpanD0zamlR9qKwOkAAtZFGpYMKTUwmfK-hqgDYtj6ZgBjKO5FFa4IBZBBP3eIussAlemRda3e-MvX5tdHeRWicu0tSGG6oEhiWs6ozJ8yEy2AHHhve1Li2CZK-A6gHs1TvMyfi4XwN375F6NXGm3UrUHZM1mD8ntUX02_4j86VKA6NMLWt_DsoZiPLw6nmU0V5k5n-gT2hsOvnXpJKdFbl0xpQCZKYb6UqV1gawVyzZLHnKK2_vwYamu2KTgIdDeXOkWHlSkuLGUU9xfpnh3Hvo0dA4-wg9FMRit7t4zMPV-YRGG9RhLpzjq_DE5vBFpPiGtbJbZZ4QGKjSB9gVzKbhNcaRiriU059roNOKuTTYXQkt0TaCOeTymSeNImUlSyrdN3jZV5xVryHWVtlHyTQUk-i5_mJ0eJ7XdSGzKpVUidDxyTDqjBOYfANwYBs53nLXJxkJvktr65MlyrrTJm6YY7AYeBqnMzgqowzn8JYxz0SZPKzVrRhLF4HLJDpSIFQVcGepqSTY5KbnJA-QQlAE03Sx19d-vn-ztDMovz___Cq_Jnf7BaJgMB-P9F-RuCCCzCjjdIK2z08K-BFB4lr6qZyIl32968v8FkTh16w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKkSouiDcpBQwCqZel-_Cu7QNCgTRq-hISVMpt8frRRgqbtNtQ9a9x5ocx491sGrVw6yVaxY99eGb8jT3-hpB3hbQ2LKIikEKLgBlwWEUobSAVMzp1MAH7HEsHh9nOEdsdpsMV8nt-FgbDKuc20RtqM9G4Rr6FWZTQO4jSLdeERXzt9T9NTwPMIIU7rfN0GrWI7NnLC3Dfqo-DHoz1-zjub3__shM0GQYCnSYsCxwrCoc7b0yrMNZWRkgHFrMk1jB5SKlFyJQNNcAclmXSMQN4R3MprHBRJqIE-r1D7vIkjVDH-JC36zvIspL5BLYxBu2BSckaYiMfSGRGHwB74QnuK9OhzxpwE9S9HrF5FUn7qbD_gNxvMCzt1kL3kKzY8hFZO2h26R-TP10KYH18SZsTWdZQjIxXx5OSVqo0FyN9Qrf3B9-6dFTRWWXhU1MAzxSDfqnSeob8FYs2C0Zyigv98GOprnml4CbQ3lzrFm40K3CJqaK40kzxFD30aegUvIWfimJYWtN9YEAJf2ERBvgYS8f41NUTcnQrY_mUrJaT0j4nNFKxiXQomCvAgcoSlXEtoTnXRhcJdx2yOR-0XDdU6pjRY5y3LpUZ5X58O-RtW3Va84fcVOkzjnxbASm__R-Ts-O8sSC5Lbi0SsSOJ45JZ5TATASAIOPIhY6zDtmYy03e2KEqX2hNh7xpi8GC4LaQKu1kBnU4h0_COBcd8qwWs_ZJkgycL5lCiVgSwKVHXS4pRyeepTxCNkEZQdNNL6v_fv18tzfwF-v_f4XXZA1UPt8fHO69IPdiQJt15OkGWT0_m9mXgA7Pi1deDSn5cdt6_xeueHi7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+newly+developed+glucagon+sandwich+ELISA+is+useful+for+more+accurate+glucagon+evaluation+than+the+currently+used+sandwich+ELISA+in+subjects+with+elevated+plasma+proglucagon-derived+peptide+levels&rft.jtitle=Journal+of+diabetes+investigation&rft.au=Kobayashi%2C+Masaki&rft.au=Maruyama%2C+Nobuhiro&rft.au=Yamamoto%2C+Yukako&rft.au=Togawa%2C+Takeshi&rft.date=2023-05-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2040-1116&rft.eissn=2040-1124&rft.volume=14&rft.issue=5&rft.spage=648&rft.epage=658&rft_id=info:doi/10.1111%2Fjdi.13986&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-1116&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-1116&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-1116&client=summon